Comparative Pharmacology
Head-to-head clinical analysis: PRED FORTE versus PREDNISOLONE EYE DROPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRED FORTE versus PREDNISOLONE EYE DROPS.
PRED FORTE vs Prednisolone Eye Drops
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, causing inhibition of phospholipase A2, arachidonic acid release, and synthesis of inflammatory mediators. Reduces inflammation by suppressing leukocyte infiltration and cytokine production.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
1-2 drops in the conjunctival sac every 1-2 hours during the day and every 4 hours at night initially, then taper to every 4-8 hours as inflammation resolves. Severe cases may require hourly dosing.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
None Documented
None Documented
2-3 hours (terminal) after IV administration; for topical ophthalmic use, systemic half-life is similar but local ocular half-life is prolonged due to corneal reservoir.
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 80% of elimination, with biliary/fecal elimination <20%.
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
Category C
Category A/B
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid